Neuroleptic malignant syndrome. When levodopa withdrawal is the cause

Postgrad Med. 1991 Apr;89(5):175-8, 180. doi: 10.1080/00325481.1991.11700900.


Neuroleptic malignant syndrome has been described in patients receiving dopamine antagonists and in a few patients after withdrawal of dopaminergic antiparkinson therapy. Complications affect almost all organ systems and can be life-threatening. Most patients have fever, altered level of consciousness, bradykinesia, and rigidity. Treatment includes withdrawal of the causative agent and supportive therapy for complications. When withdrawal of a dopaminergic medication is the suspected cause, the agent should be reinstated.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Carbidopa / adverse effects
  • Humans
  • Levodopa / adverse effects*
  • Male
  • Neuroleptic Malignant Syndrome / diagnosis
  • Neuroleptic Malignant Syndrome / etiology*
  • Parkinson Disease / drug therapy
  • Substance Withdrawal Syndrome*


  • Levodopa
  • Carbidopa